vs
EXACT SCIENCES CORP（EXAS）与EPLUS INC（PLUS）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是EPLUS INC的1.4倍（$878.4M vs $614.8M），EPLUS INC净利率更高（5.7% vs -9.8%，领先15.5%），EXACT SCIENCES CORP同比增速更快（23.1% vs 20.3%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 2.3%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
ePlus Inc.是美国的科技咨询解决方案提供商，业务覆盖网络安全、云计算、网络架构、协作办公、人工智能及前沿技术领域，为超5000家客户提供定制化解决方案、专业咨询与托管服务，助力企业实现数字化转型与技术升级。
EXAS vs PLUS — 直观对比
营收规模更大
EXAS
是对方的1.4倍
$614.8M
营收增速更快
EXAS
高出2.8%
20.3%
净利率更高
PLUS
高出15.5%
-9.8%
两年增速更快
EXAS
近两年复合增速
2.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $614.8M |
| 净利润 | $-86.0M | $35.1M |
| 毛利率 | 70.1% | 25.8% |
| 营业利润率 | -9.4% | 7.1% |
| 净利率 | -9.8% | 5.7% |
| 营收同比 | 23.1% | 20.3% |
| 净利润同比 | 90.1% | 45.2% |
| 每股收益（稀释后） | $-0.45 | $1.33 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPLUS
| Q4 25 | $878.4M | $614.8M | ||
| Q3 25 | $850.7M | $608.8M | ||
| Q2 25 | $811.1M | $637.3M | ||
| Q1 25 | $706.8M | — | ||
| Q4 24 | $713.4M | $493.2M | ||
| Q3 24 | $708.7M | $493.4M | ||
| Q2 24 | $699.3M | $535.7M | ||
| Q1 24 | $637.5M | — |
净利润EXASPLUS
| Q4 25 | $-86.0M | $35.1M | ||
| Q3 25 | $-19.6M | $34.9M | ||
| Q2 25 | $-1.2M | $37.7M | ||
| Q1 25 | $-101.2M | — | ||
| Q4 24 | $-864.6M | $24.1M | ||
| Q3 24 | $-38.2M | $31.3M | ||
| Q2 24 | $-15.8M | $27.3M | ||
| Q1 24 | $-110.2M | — |
毛利率EXASPLUS
| Q4 25 | 70.1% | 25.8% | ||
| Q3 25 | 68.6% | 26.6% | ||
| Q2 25 | 69.3% | 23.3% | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | 25.4% | ||
| Q3 24 | 69.4% | 25.8% | ||
| Q2 24 | 69.8% | 23.7% | ||
| Q1 24 | 70.0% | — |
营业利润率EXASPLUS
| Q4 25 | -9.4% | 7.1% | ||
| Q3 25 | -3.0% | 8.0% | ||
| Q2 25 | -0.3% | 5.7% | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | 3.3% | ||
| Q3 24 | -5.6% | 5.5% | ||
| Q2 24 | -3.8% | 5.9% | ||
| Q1 24 | -16.7% | — |
净利率EXASPLUS
| Q4 25 | -9.8% | 5.7% | ||
| Q3 25 | -2.3% | 5.7% | ||
| Q2 25 | -0.1% | 5.9% | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | 4.9% | ||
| Q3 24 | -5.4% | 6.3% | ||
| Q2 24 | -2.3% | 5.1% | ||
| Q1 24 | -17.3% | — |
每股收益（稀释后）EXASPLUS
| Q4 25 | $-0.45 | $1.33 | ||
| Q3 25 | $-0.10 | $1.32 | ||
| Q2 25 | $-0.01 | $1.43 | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | $0.91 | ||
| Q3 24 | $-0.21 | $1.17 | ||
| Q2 24 | $-0.09 | $1.02 | ||
| Q1 24 | $-0.60 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $326.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.1B |
| 总资产 | $5.9B | $1.8B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPLUS
| Q4 25 | $964.7M | $326.3M | ||
| Q3 25 | $1.0B | $402.2M | ||
| Q2 25 | $858.4M | $480.2M | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | $253.1M | ||
| Q3 24 | $1.0B | $187.5M | ||
| Q2 24 | $946.8M | $349.9M | ||
| Q1 24 | $652.1M | — |
股东权益EXASPLUS
| Q4 25 | $2.4B | $1.1B | ||
| Q3 25 | $2.5B | $1.0B | ||
| Q2 25 | $2.5B | $1.0B | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | $962.3M | ||
| Q3 24 | $3.2B | $947.0M | ||
| Q2 24 | $3.2B | $921.9M | ||
| Q1 24 | $3.1B | — |
总资产EXASPLUS
| Q4 25 | $5.9B | $1.8B | ||
| Q3 25 | $5.9B | $1.8B | ||
| Q2 25 | $5.8B | $1.8B | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.9B | $1.8B | ||
| Q3 24 | $6.7B | $1.7B | ||
| Q2 24 | $6.7B | $1.7B | ||
| Q1 24 | $6.4B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $-87.4M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | -2.49× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPLUS
| Q4 25 | $151.7M | $-87.4M | ||
| Q3 25 | $219.9M | $-34.8M | ||
| Q2 25 | $89.0M | $-99.0M | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | $65.7M | ||
| Q3 24 | $138.7M | $-21.6M | ||
| Q2 24 | $107.1M | $97.1M | ||
| Q1 24 | $-82.3M | — |
自由现金流EXASPLUS
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | — |
自由现金流率EXASPLUS
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | — |
资本支出强度EXASPLUS
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — | ||
| Q1 24 | 5.9% | — |
现金转化率EXASPLUS
| Q4 25 | — | -2.49× | ||
| Q3 25 | — | -1.00× | ||
| Q2 25 | — | -2.63× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.72× | ||
| Q3 24 | — | -0.69× | ||
| Q2 24 | — | 3.55× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PLUS
| All Others Customer End Market | $107.0M | 17% |
| Technology Customer End Market | $89.4M | 15% |
| Health Care Customer End Market | $81.5M | 13% |
| Financial Services Customer End Market | $66.1M | 11% |
| Professional Services Reporting Unit | $64.1M | 10% |
| Security | $61.1M | 10% |
| State And Local Government And Educational Institutions | $59.9M | 10% |
| Managed Services Reporting Unit | $48.8M | 8% |
| Other Product | $21.1M | 3% |
| Collaboration | $13.4M | 2% |
